See more : Solvbl Solutions Inc. (SOLBF) Income Statement Analysis – Financial Results
Complete financial analysis of EDAP TMS S.A. (EDAP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of EDAP TMS S.A., a leading company in the Medical – Devices industry within the Healthcare sector.
- Amaroq Minerals Ltd. (AMRQ.V) Income Statement Analysis – Financial Results
- Design Milk Co Limited (AHAHF) Income Statement Analysis – Financial Results
- Zymergen Inc. (ZY) Income Statement Analysis – Financial Results
- AB Electrolux (publ) (ELUX-B.ST) Income Statement Analysis – Financial Results
- Moro Corporation (MRCR) Income Statement Analysis – Financial Results
EDAP TMS S.A. (EDAP)
About EDAP TMS S.A.
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 60.42M | 55.11M | 44.07M | 41.66M | 44.91M | 39.18M | 35.75M | 35.61M | 32.25M | 26.79M | 24.08M | 26.07M | 22.29M | 23.71M | 24.89M | 23.05M | 22.36M | 20.27M | 20.79M | 22.15M | 18.44M | 19.98M | 24.01M | 27.33M | 19.16M | 23.19M | 32.73M |
| Cost of Revenue | 36.01M | 30.92M | 25.64M | 23.28M | 23.91M | 22.27M | 20.94M | 19.20M | 18.47M | 15.58M | 14.76M | 15.63M | 13.44M | 14.25M | 14.21M | 13.96M | 13.17M | 11.95M | 12.30M | 13.67M | 13.07M | 11.51M | 15.22M | 14.23M | 10.77M | 11.60M | 16.18M |
| Gross Profit | 24.41M | 24.19M | 18.42M | 18.38M | 21.00M | 16.92M | 14.81M | 16.41M | 13.79M | 11.20M | 9.32M | 10.43M | 8.86M | 9.46M | 10.67M | 9.10M | 9.19M | 8.32M | 8.49M | 8.48M | 5.37M | 8.47M | 8.79M | 13.10M | 8.39M | 11.60M | 16.55M |
| Gross Profit Ratio | 40.40% | 43.90% | 41.81% | 44.11% | 46.76% | 43.17% | 41.43% | 46.08% | 42.74% | 41.82% | 38.70% | 40.03% | 39.73% | 39.88% | 42.89% | 39.47% | 41.11% | 41.05% | 40.83% | 38.29% | 29.12% | 42.37% | 36.62% | 47.92% | 43.77% | 50.00% | 50.56% |
| Research & Development | 6.96M | 4.92M | 3.40M | 4.50M | 3.73M | 4.09M | 3.88M | 3.87M | 2.69M | 2.93M | 2.60M | 2.66M | 2.44M | 3.27M | 3.65M | 4.26M | 3.20M | 2.44M | 1.78M | 1.52M | 3.06M | 3.19M | 3.44M | 3.98M | 3.14M | 3.24M | 3.36M |
| General & Administrative | 14.63M | 7.15M | 5.90M | 4.34M | 4.22M | 3.59M | 3.43M | 3.30M | 3.20M | 3.33M | 3.20M | 3.19M | 3.04M | 3.32M | 3.82M | 3.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 22.63M | 16.38M | 10.73M | 9.28M | 10.85M | 10.55M | 9.53M | 8.86M | 7.41M | 6.68M | 6.28M | 6.62M | 5.87M | 6.68M | 6.40M | 5.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 37.26M | 23.53M | 16.63M | 13.61M | 15.07M | 14.14M | 12.95M | 12.15M | 10.61M | 10.01M | 9.48M | 9.81M | 8.92M | 10.01M | 10.22M | 9.55M | 9.87M | 8.70M | 8.03M | 7.47M | 10.44M | 9.92M | 9.59M | 11.51M | 11.57M | 12.96M | 12.55M |
| Other Expenses | 1.00K | 0.00 | 0.00 | -1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 174.57K | 0.00 | 0.00 | -282.00K | 0.00 | 0.00 | 0.00 | 0.00 | 224.28K | 267.46K | 0.00 | 317.20K | -23.03K | 136.27K | 92.16K | 1.35M | 1.80M | 1.53M | 1.45M |
| Operating Expenses | 44.22M | 28.45M | 20.04M | 18.11M | 18.80M | 18.23M | 16.84M | 16.02M | 13.30M | 12.94M | 12.07M | 12.46M | 11.35M | 13.27M | 13.87M | 13.80M | 13.29M | 11.41M | 9.81M | 9.31M | 13.48M | 13.25M | 13.12M | 16.84M | 16.51M | 17.74M | 17.36M |
| Cost & Expenses | 80.24M | 59.37M | 45.68M | 41.39M | 42.71M | 40.50M | 37.77M | 35.22M | 31.77M | 28.52M | 26.84M | 28.10M | 24.79M | 27.53M | 28.09M | 27.76M | 26.46M | 23.36M | 22.12M | 22.98M | 26.55M | 24.76M | 28.33M | 31.07M | 27.28M | 29.33M | 33.55M |
| Interest Income | 1.31M | 404.00K | 10.00K | 10.00K | 20.00K | 19.00K | 18.00K | 21.00K | 18.00K | 31.00K | 59.00K | 126.00K | 185.00K | 265.00K | 252.00K | 412.00K | 331.28K | 224.28K | 186.59K | 146.06K | 177.07K | 455.52K | 992.41K | 0.00 | 0.00 | 511.60K | 0.00 |
| Interest Expense | 232.00K | 168.00K | 52.00K | 108.00K | 165.00K | 111.00K | 44.00K | 57.00K | 64.00K | 65.00K | 1.97M | 2.07M | 875.00K | 2.14M | 1.45M | 1.41M | 378.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.91M | 1.61M | 2.00M | 2.06M | 2.07M | 1.52M | 1.48M | 1.07M | 1.00M | 900.00K | 1.18M | 931.00K | 1.41M | 1.23M | 1.80M | 1.79M | 1.30M | 1.26M | 1.20M | 1.05M | 981.42K | 1.12M | 1.10M | 1.35M | 1.80M | 1.53M | 1.45M |
| EBITDA | -18.39M | -323.00K | 309.00K | 2.37M | 2.06M | 295.00K | 1.32M | 1.38M | 1.45M | 569.00K | -1.74M | -1.15M | -2.93M | -8.41M | -4.44M | 4.85M | -3.90M | -1.13M | -119.89K | 614.49K | -7.13M | -3.66M | -3.22M | -2.40M | -6.32M | -4.60M | 636.36K |
| EBITDA Ratio | -30.43% | -11.22% | -9.02% | 3.91% | 4.60% | -4.73% | -3.13% | 0.81% | -0.66% | -4.88% | -6.33% | -13.57% | -13.14% | -19.83% | -4.63% | -10.95% | -5.43% | -5.60% | -1.67% | 2.77% | -34.83% | -21.76% | -62.67% | -77.40% | -42.65% | -14.71% | -1.11% |
| Operating Income | -19.81M | -4.26M | -1.61M | -477.00K | 185.00K | -1.32M | -2.03M | 392.00K | 488.00K | -1.74M | -2.76M | -2.03M | -2.50M | 3.82M | 3.20M | 4.70M | 4.10M | 3.09M | 1.32M | 829.15K | 8.11M | 4.78M | 5.12M | 3.75M | -8.12M | 6.14M | -818.18K |
| Operating Income Ratio | -32.79% | -7.72% | -3.66% | -1.14% | 0.41% | -3.36% | -5.67% | 1.10% | 1.51% | -6.48% | -11.44% | -7.79% | -11.20% | 16.10% | 12.87% | 20.40% | 18.31% | 15.27% | 6.36% | 3.74% | 43.96% | 23.93% | 21.34% | 13.71% | -42.36% | 26.47% | -2.50% |
| Total Other Income/Expenses | -720.00K | 2.16M | 2.51M | -711.00K | 2.01M | 1.34M | 1.73M | 4.05M | -1.40M | 1.34M | -2.13M | -5.33M | 1.95M | -7.96M | -10.90M | -3.06M | -9.67M | -6.47M | -2.28M | -1.70M | -17.18M | -8.66M | 2.91M | 8.32M | 1.61M | -13.22M | 909.09K |
| Income Before Tax | -20.53M | -2.10M | 893.00K | -1.19M | 2.19M | 20.00K | -294.00K | 4.44M | -907.00K | -396.00K | -4.89M | -7.36M | -543.00K | -11.78M | -7.69M | 1.11M | -5.58M | -3.37M | -959.98K | -870.46K | -9.07M | -3.88M | 8.03M | 12.07M | -6.51M | -7.08M | 90.91K |
| Income Before Tax Ratio | -33.98% | -3.80% | 2.03% | -2.85% | 4.88% | 0.05% | -0.82% | 12.48% | -2.81% | -1.48% | -20.29% | -28.23% | -2.44% | -49.68% | -30.92% | 4.79% | -24.95% | -16.65% | -4.62% | -3.93% | -49.21% | -19.40% | 33.46% | 44.15% | -33.95% | -30.51% | 0.28% |
| Income Tax Expense | 644.00K | 837.00K | 193.00K | 516.00K | 679.00K | 358.00K | 388.00K | 602.00K | 759.00K | 116.00K | 135.00K | 118.00K | 395.00K | 939.00K | 72.00K | -492.00K | -139.92K | 56.07K | 103.85K | 278.11K | -113.55K | 166.77K | 883.39K | 323.68K | -256.40K | 85.27K | -90.91K |
| Net Income | -21.18M | -2.93M | 700.00K | -1.70M | 1.51M | -338.00K | -681.00K | 3.84M | -1.67M | -512.00K | -5.02M | -7.48M | -938.00K | -12.72M | -7.77M | 1.60M | -5.44M | -3.43M | -1.06M | -1.15M | -8.96M | -4.04M | 7.15M | 11.74M | -6.25M | -7.16M | 181.82K |
| Net Income Ratio | -35.05% | -5.32% | 1.59% | -4.09% | 3.37% | -0.86% | -1.91% | 10.79% | -5.17% | -1.91% | -20.85% | -28.68% | -4.21% | -53.64% | -31.21% | 6.93% | -24.32% | -16.93% | -5.12% | -5.18% | -48.59% | -20.24% | 29.78% | 42.97% | -32.61% | -30.88% | 0.56% |
| EPS | -0.57 | -0.09 | 0.02 | -0.06 | 0.05 | -0.01 | -0.02 | 0.14 | -0.07 | -0.02 | -0.24 | -0.43 | -0.07 | -0.98 | -0.74 | 0.17 | -0.59 | -0.39 | -0.14 | -0.15 | -1.15 | -0.52 | 0.92 | 1.50 | -0.80 | -0.86 | 0.03 |
| EPS Diluted | -0.57 | -0.09 | 0.02 | -0.06 | 0.05 | -0.01 | -0.02 | 0.13 | -0.07 | -0.02 | -0.24 | -0.43 | -0.07 | -0.97 | -0.73 | 0.17 | -0.59 | -0.36 | -0.13 | -0.14 | -1.15 | -0.52 | 0.90 | 1.42 | -0.80 | -0.86 | 0.03 |
| Weighted Avg Shares Out | 37.00M | 34.39M | 32.13M | 29.15M | 29.02M | 29.00M | 28.96M | 27.82M | 23.81M | 23.60M | 20.59M | 17.38M | 13.35M | 13.01M | 10.51M | 9.58M | 9.20M | 8.82M | 7.78M | 7.78M | 7.78M | 7.77M | 7.76M | 7.78M | 7.80M | 8.32M | 6.67M |
| Weighted Avg Shares Out (Dil) | 37.00M | 34.39M | 32.42M | 29.15M | 29.62M | 29.00M | 28.96M | 29.37M | 25.02M | 23.60M | 20.59M | 17.56M | 13.35M | 13.09M | 10.57M | 9.66M | 9.20M | 9.56M | 8.37M | 8.07M | 7.82M | 7.83M | 7.94M | 8.27M | 7.80M | 8.32M | 6.67M |
EDAP Announces Interim Results from Phase 3 Study Evaluating Robotic HIFU for the Treatment of Deep Infiltrating Endometriosis
EDAP Appoints New Executive Leaders to Strengthen Europe and Middle East Commercial Operations
EDAP TMS (EDAP) Q1 2024 Earnings Call Transcript
EDAP Announces Positive Final Results from the HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy During Plenary Session at the 119th American Urological Association (AUA) Annual Meeting
EDAP to Announce First Quarter 2024 Financial Results on May 16, 2024
EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual Meeting
EDAP TMS (EDAP) Q4 2023 Earnings Call Transcript
EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024
EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis
Source: https://incomestatements.info
Category: Stock Reports